aratinga.bio is a preclinical stage company developing novel immunotherapies to treat cancer. To address unmet medical needs, aratinga.bio is developing its proprietary platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced. The use of human T cells as therapeutics and the administration of anti-checkpoints are revolutionizing the way cancer is treated. We believe investments in research capabilities including access to state-of-the-art gene transfer and nucleotide-based technologies, will help accelerate the development of new and better options for immune-oncology therapeutics
| Website | http://www.aratinga.bio |
| Employees | 3 (0 on RocketReach) |
| Founded | 2017 |
| Address | 1, Mail du Professeur Georges Mathé, Villejuif, Île-de-France 94800, FR |
| Technologies |
JavaScript
,
HTML
,
Twitter
+11 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Science and Engineering |
| Keywords | Cancer Immunotherapy, Oncology Therapeutics, Solid Tumor Therapy, Immunotherapy Development, Novel Cancer Treatments, Preclinical Drug Development, Cancer Drug Discovery, Biopharmaceutical Research, Immunological Research, Clinical Stage Biotech, Pharmaceutical Innovation, Cancer Research, Oncology Research, Therapeutic Antibodies, Targeted Cancer Therapies, Biotechnology, Drug Development, Immunotherapeutics, Preclinical Research |
Looking for a particular aratinga.bio employee's phone or email?
aratinga.bio is based in Villejuif, Île-de-France.